Saltar al contenido
Merck
  • Mutant KRAS-induced expression of ICAM-1 in pancreatic acinar cells causes attraction of macrophages to expedite the formation of precancerous lesions.

Mutant KRAS-induced expression of ICAM-1 in pancreatic acinar cells causes attraction of macrophages to expedite the formation of precancerous lesions.

Cancer discovery (2014-11-02)
Geou-Yarh Liou, Heike Döppler, Brian Necela, Brandy Edenfield, Lizhi Zhang, David W Dawson, Peter Storz
RESUMEN

Desmoplasia and an inflammatory environment are defining features of pancreatic cancer. Unclear is how pancreatic cells that undergo oncogenic transformation can cross-talk with immune cells and how this contributes to the development of pancreatic lesions. Here, we demonstrate that pancreatic acinar cells expressing mutant KRAS can expedite their transformation to a duct-like phenotype by inducing local inflammation. Specifically, we show that KRAS(G12D) induces the expression of intercellular adhesion molecule-1 (ICAM-1), which serves as chemoattractant for macrophages. Infiltrating macrophages amplify the formation of KRAS(G12D)-caused abnormal pancreatic structures by remodeling the extracellular matrix and providing cytokines such as TNF. Depletion of macrophages or treatment with a neutralizing antibody for ICAM-1 in mice expressing oncogenic Kras under an acinar cell-specific promoter resulted in both a decreased formation of abnormal structures and decreased progression of acinar-to-ductal metaplasia to pancreatic intraepithelial neoplastic lesions. We here show that oncogenic KRAS in pancreatic acinar cells upregulates the expression of ICAM-1 to attract macrophages. Hence, our results reveal a direct cooperative mechanism between oncogenic Kras mutations and the inflammatory environment to drive the initiation of pancreatic cancer.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Dexametasona, powder, BioReagent, suitable for cell culture, ≥97%
Sigma-Aldrich
DAPI, for nucleic acid staining
Sigma-Aldrich
Dexametasona, ≥98% (HPLC), powder
Sigma-Aldrich
1,1′-Dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine perchlorate, BioReagent, suitable for fluorescence, ≥98.0% (TLC)
Sigma-Aldrich
Dexametasona, powder, γ-irradiated, BioXtra, suitable for cell culture, ≥80% (HPLC)
Sigma-Aldrich
Gadolinium(III) chloride hexahydrate, 99% (titration)
Sigma-Aldrich
1,1′-Dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine perchlorate, 97%
USP
Dexametasona, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Gadolinium(III) chloride hexahydrate, 99.999% trace metals basis
Supelco
Dexametasona, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Dexametasona, meets USP testing specifications
Sigma-Aldrich
Dexametasona, tested according to Ph. Eur.
Dexametasona, European Pharmacopoeia (EP) Reference Standard
Supelco
Dexametasona, VETRANAL®, analytical standard
Dexametasona, European Pharmacopoeia (EP) Reference Standard
Dexametasona, European Pharmacopoeia (EP) Reference Standard
Dexametasona, British Pharmacopoeia (BP) Assay Standard